Bristol-Myers Squibb has selected the Medidata’s Clinical Cloud to help manage, monitor and analyze its clinical trials. Medidata’s technology platform will support BMS’ research in immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, genetically modified diseases and metabolics.
 
BMS will integrate Medidata’s data management, data analytics and risk-based monitoring (RBM) capabilities into all stages of its drug development process.
 
“Our agreement with Bristol-Myers Squibb is a great example of how the world’s best clinical researchers are increasingly relying on Medidata technology to help support advances in treatments for patients,” said Medidata’s chief executive officer Tarek Sherif. “Medidata has developed the most comprehensive cloud platform dedicated to clinical research, powered by the world’s largest data repository. With our powerful and flexible SaaS solution, we are helping our customers achieve meaningful time-to-market results, as well as giving them the data and actionable insights they need to innovate successfully.”
 
A phased rollout is under way. Medidata has selected Accenture (ACN), a global provider of a broad range of services and solutions in strategy, consulting, digital, technology and operations, to be its partner for specific elements of the project.